Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B
Science Journal of Clinical Medicine
Volume 3, Issue 6, November 2014, Pages: 117-123
Received: Oct. 22, 2014; Accepted: Nov. 5, 2014; Published: Nov. 10, 2014
Views 2744      Downloads 358
Ali Koyuncuer, Department of Pathology, Pathologist, Antakya State Hospital, Hatay, Turkey
Article Tools
Follow on us
Hepatitis B virus (HBV) infection is still a significant healthcare problem all over the world. Between January 2009 and May 2014, a total of 96 patients with chronic hepatitis B (CHB) were enrolled in study. A total of 96 CHB cases were examined. The mean total liver histological activity indices for grade and stage were 6.01±2.46, and 1.6±0.99 and the mean ALT and AST levels were 32.6 ±21.0 IU/L and 25.6 ±11.2 IU/L, respectively. The mean HBV DNA level was 8.9 x106±3.3106 IU/mL. Forty (41.7%) patients had HBV DNA <20 IU/Ml (undetectable) and 14 (14.6%) patients had HBV DNA levels between 21 and 2000 IU/mL. Of the total 96 patients, 100% were HBsAg positive, 88 (91.7%) were HBeAg negative and 8 (8.3%) were HBeAg positive. A significant correlation was found between the HBeAg serostatus, HBV DNA level and the histological activity index necroinflammatory total scores (P= 0.034 and 0.000). We found no correlation between the fibrosis score and HBeAg status (P= 0.451). However, a statistically significant difference was found between HBV DNA levels and stage of fibrosis (P= 0.048). A significant relationship was found between the HBeAg status, HBV DNA level and ALT and AST levels (P= 0.000, 0.000, 0.032, 0.024). The HBeAg status of CHB patients should not affect the treatment response or need for long-term follow-up visits with repeat ALT and HBV DNA levels. However, chronic hepatitis patients who are negative for HBeAg may need different short-term follow-up.
ALT, HBV DNA Level, HBeAg Status, Liver Histology
To cite this article
Ali Koyuncuer, Associations between HBeAg Status, HBV DNA, ALT Level and Liver Histopathology in Patients with Chronic Hepatitis B, Science Journal of Clinical Medicine. Vol. 3, No. 6, 2014, pp. 117-123. doi: 10.11648/j.sjcm.20140306.14
World Health Organization: WHO: Hepatitis B. Fact Sheet No. 204. ( (accessed 4 May 2014).
Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, Kern ER, McHugh JA, Petersen GM, Rein MF, Strader DB, Trotter HT: National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009; 49(5 Suppl):S4-S12. doi: 10.1002/hep.22946.
Lok AS: Chronic hepatitis B. N Engl J Med. 2002; 346(22):1682-3.
Lee WM: Hepatitis B virus infection. N Engl J Med. 1997; 337(24):1733-45.
Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2):97-107.
Sharma SK, Saini N, Chwla Y: Hepatitis B virus: inactive carriers. Virol J. 2005; 2:82.
Martinelli D, Fortunato F, Simsek G, Prato R: Epidemiology and Prevention of Viral Hepatitis B and C. Practical Management of Chronic Viral Hepatitis. Edited by Serviddio G. Croatia: In Tech; 2013;3-18.
Geller SA, Petrovic LM: Chronic Hepatitis (Chronic Necroinflammatory Disease of the Liver)-Grading and Staging. Biopsy Interpretation of the Liver. 2nd edition. Philadelphia: Lippincott Williams & Wilkins; 2009;97-120
Squadrito G, Spinella R, Raimondo G: The clinical significance of occult HBV infection. Ann Gastroenterol. 2014; 27(1):15-19.
Yim HJ, Lok AS: Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006; 43(2 Suppl 1):S173-81.
Kim ES, Seo YS, Keum B, Kim JH, A H, Yim HJ, Kim YS, Jeen YT, Lee HS, Chun HJ, Um SH, Duck Kim C, Ryu HS: The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers. Hepat Mon. 2011; 11(5):351-7.
Ijaz B, Ahmad W, Javed FT, Gull S, Hassan S: Revised cutoff values of ALT and HBV DNA level can better differentiate HBeAg (-) chronic inactive HBV patients from active carriers. Virol J. 2011; 8: 86.
European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85.
Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol. 2007; 20 Suppl 1:S3-14.
Gara N, Zhao X, Kleiner DE, Liang TJ, Hoofnagle JH, Ghany MG: Discordance among transient elastography, aspartate aminotransferase to platelet ratio index, and histologic assessments of liver fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2013; 11(3):303-8.e1.
Christensen C, Bruden D, Livingston S, Deubner H, Homan C, Smith K, Oh E, Gretch D, Williams J, McMahon B: Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepat. 2006; 13(10):652-8.
Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H: Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol. 2014; 86(1):131-8.
Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008; 6(12):1315-41.
Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, Vianello L, Zanuso F, Mozzi F, Milani S, Conte D, Colombo M, Sirchia G: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002; 137(1):1-10.
Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology. 2007; 45:507-39.
Keshvari M, Alavian SM, Sharafi H: How can we make decision for patients with chronic hepatitis B according to hepatitis B virus (HBV) DNA level? Hepat Mon. 2014; 5:e15285.
McMahon BJ: Chronic hepatitis B virus infection. Med Clin North Am 2014, 98:39-54.
Tong MJ, Trieu J: Hepatitis B inactive carriers: clinical course and outcomes. J Dig Dis. 2013; 14(6):311-7
Gastroenterological Society of Australia and Digestive Health Foundation: Australian and New Zealand chronic hepatitis B (CHB) recommendations. Clinical update [webpage on the Internet] Victoria, Australia: The Digestive Health Foundation; 2008. Available from: Accessed May 5, 2014.
Robotin M, Patton Y, Kansil M, Penman A, George J. Cost of treating chronic hepatitis B: comparison of current treatment guidelines. World J Gastroenterol. 2012; 18(42):6106-13.
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, REVEAL-HBV Study Group: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1):65-73.
Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, Dong JQ: Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol. 2007; 13(14):2104-7.
Alam S, Ahamd N, Alam K, Mostafa G, Khan M: Correlation between Hepatitis B Viral DNA Load and Extent of Liver Pathology in Patients with Chronic Hepatitis B. Hepatitis Monthly. 2008, 8(3):185-9
Madan K, Batra Y, Jha JK, Kumar S, Kalra N, Paul SB, Singh R, Duttagupta S, Panda SK, Acharya SK: Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.Trop Gastroenterol. 2008; 29(2):84-90.
Peng J, Luo K, Zhu Y, Guo Y, Zhang L, Hou J: Clinical and histological characteristics of chronic hepatitis B with negative hepatitis B e-antigen. Chin Med J (Engl). 2003; 116(9):1312-7.
Xiao L, Xian J, Li Y, Geng A, Yang X, Han L, Xu H: Parameters associated with significant liver histological changes in patients with chronic hepatitis B. ISRN Gastroenterol. 2014;2014:913890. doi: 10.1155/2014/913890. eCollection 2014.
Mansour-Ghanaei F, Rafiei R, Joukar F, Naghipour M, Besharati S, Aminian K, Atrkar-Roushan Z: Relationship between serum HBV DNA level and liver histology in HBV carriers with normal ALT in Guilan province, Iran. Med Sci Monit. 2010; 16(3):BR97-101.
Zacharakis G, Koskinas J, Kotsiou S, Tzara F, Vafeiadis N, Papoutselis M, Maltezos E, Sivridis E, Papoutselis K: The role of serial measurement of serum HBV DNA levels in patients with chronic HBeAg(-) hepatitis B infection: association with liver disease progression. A prospective cohort study. J Hepatol. 2008; 49(6):884-91.
Martinot-Peignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, Marcellin P: Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002; 36(4):543-6.
Papatheodoridis GV, Manolakopoulos S, Liaw YF, Lok A: Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol. 2012;57(1):196-202.
Saikia N, Talukdar R, Mazumder S, Khanna S, Tandon R: Management of patients with HBeAg-negative chronic hepatitis B. Postgrad Med J. 2007; 83(975):32-9.
Chu CJ, Hussain M, Lok AS: Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002; 36(6):1408-15.
Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ: Use of hepatitis B virus DNA quantitation to predict hepatitis B e antigen reversion in cases of chronic hepatitis B. J Clin Microbiol. 2003; 41(10):4793-5.
Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000-summary of a workshop. Gastroenterology. 2001; 120(7):1828-53.
Dancygier H: Hepatitis B. Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Volume 2. Edited by Dancygier H. Berlin Heidelberg: Springer; 2010:743-80
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
Tel: (001)347-983-5186